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Abstract Pronounced differences of interactions of camptothe- 
cin (CPT) and its derivative 7-ethyl-10-[4-(1-piperidino)-l- 
piperidino]carbonyloxycamptothecin (CPTl l ) ,  inhibitors of 
DNA topoisomerase I, with oligonucleotides were found using 
UV resonance Raman spectroscopy. 30-mer oligonucleotides 
were derived from the sequences of the topoisomerase I-induced 
and CPT-enhanced cleavage sites in SV40 DNA. CPT induces 
well-defined alterations of the oligo structure, whereas CPTl l  
interacts with oligonucleotides more weakly and in another 
manner than CPT. Formation of cleavable ternary complexes 
between CPTl l ,  topoisomerase I and oligonucleotides causes 
CPTl l  to interact with oligonucleotides in the same fashion as 
was found for its parent compound CPT, and enhances this 
interaction as compared to CPT-oligonucleotide complexes. The 
data present evidence of molecular interactions of CPTl l  with 
both other partners (topoisomerase I and oligonucleotide) of the 
ternary cleavable complex at the oligonucleotide-enzyme inter- 
face. 
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I. Introduction 
Camptothecin (CPT) isolated from the Chinese tree Camp- 
totheca acuminata (Fig. 1) and several recently synthesized 
CPT derivatives are potent antitumor agents [1]. Cytotoxicity 
of camptothecins was shown to be related to their inhibition 
of DNA topoisomerase I (topol) by stabilizing DNA-drug- 
enzyme ternary, so called cleavable, complexes and preventing 
in this way the ligation step of the enzyme action [2-5]. Mech- 
anism of formation and structure of these cleavable complexes 
are currently under intense investigation [6]. CPT is not a 
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d(5'-CAAAGTCAGGTTGATGAGCATATTTTACTC-3')2 ; oli- 
go(-), oligomer d(5'-CAAAGTCAGGTTGATTAGCATATTT- 
TACTC-3')2 
DNA intercalating drug, but it is suggested that its quasi- 
planar multiring system binds by stacking with the guanine 
at the 5'-terminus of the DNA breaks produced by topol [7]. 
Among other factors the presence of hydrolyzable c~-hydroxy- 
8-1actone ring is considered to be an important factor of CPT 
functional activity [5,8], whereas the carboxylate form of CPT 
(Fig. 1) is biologically inactive and potentially toxic [9]. Up to 
now the studies were concentrated on the parent compound 
CPT, and practically nothing is known about the features of 
interactions of CPT derivatives in the course of formation of 
ternary complexes. Here we report the first attempt o eluci- 
date some of these features for one of the CPT derivatives, 
CPTl l  (Fig. 1), which is the most advanced in clinical re- 
search [1]. Our studies were performed using 30-mer oligonu- 
cleotides (Fig. 1) derived from the sequences of the topoi- 
induced (oligo(-)) and CPT-enhanced (oligo(+)) cleavage 
sites in SV40 DNA [10]. Cleavage of both oligonucleotides 
by topol was shown to occur with similar intensity and at 
the same position as in SV40 DNA [7]. An enhanced cleavage 
of oligo(+) and weaker cleavage of oligo(-) by topol were 
observed in the presence of CPT and found to be in qualita- 
tive agreement with the cleavage pattern induced by the drug 
in SV40 DNA [7,10]. Though a unique cleavage pattern was 
reported for CPT and its analogs [5], the data presented in 
this paper give evidence that substitutions (at least for CPT11) 
affect strongly the mode of the drug interaction with oligonu- 
cleotides. The results obtained provide proof for the interac- 
tion of CPTl l  with both topol and oligonucleotide at the 
oligonucleotide-enzyme interface of the ternary cleavable 
complex. 
2. Materials and methods 
Oligonucleotides (Fig. 1) were purchased from Eurogentec (Bel- 
gium). Calf thymus topol (25 units/~tg) and CPTll were supplied 
by Rhone-Poulenc Rorer, S.A. CPT was purchased from Sigma. All 
other chemicals were of analytical reagent grade and all solvents were 
of HPLC grade. 
One unit of topol was defined as described earlier [11]. To obtain 
duplex oligonucleotides the annealing procedure was performed as 
described elsewhere [7]. Complexes and reaction mixtures of CPT or 
CPT11 with oligonucleotides, CPTII with topol and oligonucleotides 
as well as oligonucleotide with topol were prepared by mixing the 
components in 40 ~tl of the reaction buffer (20 mM Tris-HC1 (pH 7.0), 
60 mM KC1, 10 mM MgC12, 0.5 mM EDTA, and 0.5 mM dithio- 
threitol) at concentrations of 10 ~M of the enzyme, 20 ~tM of the 
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3" GTTTCAGTCCAACTA ,~TCGTATAA~TC-~G -5' 
Fig. 1. Chemical structures of CPT and CPTI1. Base sequences of 
the studied oligonucleotides. Position of topoi-induced DNA cleav- 
age in SV40 DNA and altered nucleotide bases are marked. 
oligonucleotide and 20 or 40 gM of the drug. After mixing the com- 
plexes were incubated at 20°C for 15 min, and then placed in the cell 
for UV RR measurement. Preparing a complex a stock solution of 15 
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mM CPT or CPTI1 in DMSO was pre-diluted in the buffer at 4°C 
and immediately mixed with the other components in the necessary 
proportion. At the conditions used (pH 7.0, t = 20°C) kinetics of hy- 
drolysis of the lactone ring of CPT or CPT11 was very slow (rate 
constant < 0.48 h -1 [12,13]), and the drug was in lactone form during 
the spectrum recording. Carboxylate form of CPT11 was prepared by 
pre-diluting the drug in the buffer (pH 7.0, t= 20°C) and storing it for 
12 h before addition to the reaction mixture. 
The excitation of Raman spectra at 257.27 nm (5 mW) was per- 
formed with a Spectra Physics Ar + cw laser (model 2025-3) equipped 
with a home-made intracavity second harmonic generation system. 
UV RR spectra were accumulated with resolution ca. 8 cm -1 using 
the spectrograph module of a multichannel XY-UV spectrometer (Di- 
lor, France). The sample solution (40 pl) was continuously stirred in a 
small quartz cell (3 ×3 mm) with a Hellma magnetic stirrer (model 
CUV-O-STIR 333) supplied with a small (2 mm) stir bar to avoid 
photodegradation during measurement. Comparing three consecutive 
records (an average of 16 accumulations at 10-15 s integration time) 
the probable time-dependent and irradiation-induced spectral changes 
were evaluated. Three independent experiments were performed to 
test the reproducibility of the results. The 3400 cm a band of water 
was used as internal standard of intensity to normalize and compare 
the spectra as well as for simulation of the spectra of complexes by 
combination of the spectra of individual components. 
3. Results and discussion 
3.1. General description of the UV RR spectra of 
oligonucleotides, topol and drugs 
Compar ing  relative intensit ies o f  the UV RR spectra o f  
ol igonucleotides, topo l ,  CPT11 and CPT (Fig. 2, I), the con- 
tr ibut ion o f  each component  to the spectra o f  b inary and 
ternary complexes was evaluated. The dominance  of  the oli- 
gonucleot ide signals was observed ue to the strong resonance 
o f  the excitat ion wavelength with electronic transit ions o f  the 
nucleot ide bases. V ibrat ional  modes  of  deoxyr ibose and phos-  
phate backbone being out o f  resonance did not  contr ibute to 
the UV RR spectra o f  the ol igonucleotides. The very similar 
"i. 
z3Lo ~ 
a N 
~o ~o ~-o  o c0o2 ° 
~mo o 
m m o ~0 o~ 
1800 1600 1400 1200 1BOO 1600 1400 1200 
WAVENUMBER / cm -1  WAVENUMBER / cm-1  
o o 
• ~o E-" -¢ 
- 
f__, 
Fig. 2. I: UV RR spectra of oligo(+) (a), topoi (b), CPTl l  (c), and CPT (d). The spectra of ol igo(-) and oligo(+) are very similar. The signal 
of water has been subtracted. Fluorescence background was subtracted from the spectra of the enzyme and drugs. The same scale of intensity 
was used for all spectra except for the CPT one to show the relative intensity of the spectra. [oligo(+)] = 20 gM, [CPT11]= 20 pM, [CPT] = 20 
gM, [topoi]= 10 pM. II: UV RR spectrum of oligo(+) (a). Simulated spectrum of oligonucleotide (b) obtained as the sum of UV RR spectra 
of dAMP (c), dGMP (d), dTMP (e), dCMP (f). The same scale of intensity was used to show the relative contribution of each type of nucleo- 
tide in the overall intensity of the oligonucleotide spectrum. 
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Fig. 3. Solid lines: UV RR spectra of CPT-oligo(-) (a), CPT-oli- 
go(+) (b), CPTI 1-oligo(-) (c) and CPT11-oligo(+) (d) reaction mix- 
tures. Dashed lines: simulated spectra of the corresponding mixtures 
obtained as the sum of normalized UV RR spectra of pure compo- 
nents. Italics are used to mark the bands affected by complex for- 
mation. The signals of water and fluorescence background have 
been subtracted. For spectra (a), (b) and (d): [CPT]--20 p.M, 
[oligo(+)] =20 p.M, [oligo(--)] = 20 p.M, [CPT11] = 20 p.M. For spec- 
trum (c): [CPT11] = 40 p.M, [oligo(-)] = 20 p.M. See text for details. 
UV RR spectra were recorded for both duplex oligonucleo- 
tides because their sequences differed only in two nucleotide 
bases. Simulating the spectrum of oligonucleotide by super- 
position of the deoxynucleotide spectra (Fig. 2, II), the vibra- 
tions of adenine, guanine, thymine and cytosine bases were 
concluded to contribute to the oligonucleotide spectrum ca. 
45%, 35%, 11% and 9% of integral intensity, respectively. The 
contribution of cytosine was very weak at any excitation in 
the region of 240-300 nm due to its small Raman cross-sec- 
tions as compared with other nucleotides [14]. The intensities 
of the thymine bands were found to be reduced markedly due 
to a stacking induced hypochromism within double-stranded 
helixes [15,16]. A tentative assignment of the oligonucleotide 
bands is shown in Fig. 2, II. 
The UV RR spectrum of topol (Fig. 2, I,b) consists of the 
bands of aromatic amino acid residues and amide bands of 
the polypeptide backbone [17]. CPT and CPTl l  exhibit a 
strong electronic transition at 254 nm, thus enabling detection 
of their spectra at low concentrations when the 257 nm ex- 
citation is used (Fig. 2 I,c,d). The spectrum of CPT is weaker 
than the CPTl l  one. The UV RR spectra of lactone and 
carboxylate forms of the drugs were found to be similar lead- 
ing us to the conclusion that vibrational modes of c~-hydroxy- 
8-1actone ring were weakly coupled with the 254 nm electronic 
transition of the drugs. 
3.2. The UV RR spectra of the oligonucleotides in the presence 
of the drugs 
On adding CPT to oligonucleotides the UV RR spectra of 
both oligo(-) and oligo(+) were found to be strongly per- 
turbed (Fig. 3a,b) clearly indicating the occurrence of interac- 
tions between the drug and the oligonucleotides. A decrease in 
the intensity of the 1484 cm 1 (A, G) and 1339 cm -1 (A, G), 
and to a lesser extent he 1652 cm -1 (T, G) and 1255 cm -1 (T, 
C) bands was observed both in the spectrum of CPT-oligo(-) 
and in that of CPT-oligo(+). These similar spectral changes 
assume the same type of interaction between the drug and 
both oligonucleotides being independent of the existence of 
a CPT-dependent cleavage site. The only feature that can be 
tentatively ascribed to some specific interactions of the drug 
with oligo(+) induced by the altered (but only in the two 
nucleotide bases) oligonucleotide s quence is a lack of the 
1427 cm 1 (A, G) band as compared to the spectrum of 
CPT-oligo(-). 
In contrast to CPT, the CPT11-induced changes of the oli- 
gonucleotide signals were found to be weak and were detected 
only in the spectrum of CPTl l -ol igo(-)  (Fig. 3c). An in- 
creased drug/oligo molar ratio was used to observe these 
changes clearly. The changes included a moderate increase 
in the intensity of the 1580 cm -1 (G, A), 1514 cm -1 and 
1339 cm -1 (A, G) bands as well as both intensity increase 
and frequency shifts of the 1610 cm -1 (G, A) and 1422 
cm -1 (A, G) bands. These spectral features differed obviously 
from those observed in the CPT-oligonucleotide spectra (Fig. 
3a,b). The spectrum of CPT11-oligo(+) (Fig. 3d) was found to 
coincide with the superposition of the free CPT11 and oil- 
go(+) spectra (even at the increased rug/oligo molar ratio), 
indicating an absence of detectable interaction between the 
drug and oligo(+). These observations suggest a pronounced 
alteration of the ability of this derivative to interact with 
DNA as compared to CPT itself. It is reasonable to conclude 
that substitutions at the 10 and 7 positions of the drug mole- 
cule (Fig. 1) make weaker or even exclude the interactions 
between the conjugated ring system (hE  rings) of the drug 
and oligonucleotides. The effect of substitutions seems to de- 
pend on the structure of the oligonucleotide asit follows from 
the differences of CPT11 action on oligo(-) and oligo(+). 
3.3. The UV RR spectra of the ternary complexes 
A strong decrease in the 1339 cm -1 (A, G) and 1484 cm -1 
(A, G) band intensity was observed in the spectra of the 
CPTll-topol-oligo(--) (Fig. 4a) and CPTll-topol-oligo(+) 
(Fig. 4b) ternary complexes. These spectral features were 
not observed in the spectra of the complexes formed between 
the oligonucleotides and CPTl l  (Fig. 3c,d) nor were they 
induced by addition of topol to oligo(+) (Fig. 4d) or by 
mixing the carboxylate form of CPTl l  with oligo(+) and 
topol (Fig. 4c). Therefore, their appearance is due to con- 
certed action of the drug and topol on the oligonucleotides. 
It should be noted that similar but less pronounced features 
were observed in the spectra of CPT with oligonucleotides 
(Fig. 3a,b). It suggests that topol stimulates the mode of 
interaction between CPTl l  and oligonucleotides which is a 
characteristic of the parent compound CPT, and enhances 
this interaction. These observations confirm the suggestion 
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of oligo(+) can be suggested. In contrast, the lactone form of 
CPT11 seems to interact with both guanine and adenine bases 
within the CPT11-topol-ol igo(+) complex (Fig. 4b). 
Considering the features of the interactions within the ter- 
nary complexes, an intensity increase of the 1670 cm -~ band 
and a decrease of the 1375 and 1250 cm -a bands of o l igo(- )  
as compared with oligo(+) should be noted. The 1670 cm 1 
feature should be assigned to the thymine band, which ap- 
peared due to the splitting of the 1652 cm -~ band into 
1670/1652 cm 1 doublet [19]. Taken together, this 1670/1652 
cm -1 doublet and these 1375, 1250 cm 1 bands correspond to 
the most intensive bands in the spectrum of dTMP (Fig. 2, 
II,e). Therefore, thymine bases are more affected in oligo(--) 
than in oligo(+) upon ternary complex formation. This corre- 
lates with the fact that the cleavage site of o l igo(- )  is enriched 
by thymine bases as compared to that of oligo(+). It can be 
supposed that alteration of the oligonucleotide sequence 
modifies the structure of duplex oligonucleotides and changes 
the accessibility of the thymine bases for the interaction with 
CPT11 and/or topol in the ternary complexes. 
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Fig. 4. Solid lines: UV RR spectra of topol-CPTll-oligo(-) (a), 
topol-CPTl 1-oligo(+) (b), topol-CPTl 1-oligo(+) (carboxylate form) 
(c) and the topol-oligo(+) (d) complexes. Dashed lines: simulated 
spectra of the corresponding complexes obtained as the sum of the 
UV RR spectra of pure components. Italics are used to mark the 
bands affected by the complex formation. The signals of water and 
fluorescence background have been subtracted. [CPTII]=20 ~aM, 
[oligo(+)] = 20 p_M, [oligo(-)] = 20 ~tM, [topoi] = 10 laM. 
that camptothecins interact with an asymmetrical receptor site 
of the enzyme or enzyme-DNA complex [5]. The binding of 
CPT l l  to this site was detected in our spectra in a form of 
specific re-orientation of the molecule which led the conju- 
gated ring system of the drug to be accessible to the interac- 
tion with the oligonucleotides. The appearance of the interac- 
tion features of the CPT derivative in dependence on whether 
oligonucleotide alone or together with topol is added to the 
drug is consistent with recent findings [11,18], where some 
biological effects induced by different modes of binding with 
DNA,  topoisomerases and in ternary complexes were ob- 
served for the derivatives of intoplicine. 
A moderate decrease in the 1484 cm 1 band intensity of the 
spectrum of the carboxylate CPT1 l-topol-ol igo(+) (Fig. 4c) 
shows that even a carboxylate form of CPT11 interacts with 
the oligonucleotide in the presence of topol.  At the same time 
some specific interactions, in particular manifesting themselves 
by the decreasing of the 1339 cm a band (Fig. 4a,b), disap- 
pear after the opening of the lactone ring. Since the adenine 
bases contribute mainly to the 1339 cm -1 band of the oligo- 
nucleotide, whereas the 1484 cm -1 band is equally attribnted 
to both guanine and adenine bases (Fig. 2, II), a predominant 
interaction of the carboxylate form of CPT l l  with guanines 
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